...
首页> 外文期刊>Journal of interferon and cytokine research: The official journal of the International Society for Interferon and Cytokine Research >Peripheral Blood Cells from Patients with Autoimmune Addison's Disease Poorly Respond to Interferons In Vitro, Despite Elevated Serum Levels of Interferon-Inducible Chemokines.
【24h】

Peripheral Blood Cells from Patients with Autoimmune Addison's Disease Poorly Respond to Interferons In Vitro, Despite Elevated Serum Levels of Interferon-Inducible Chemokines.

机译:尽管血清中干扰素诱导的趋化因子水平升高,但患有自身免疫性艾迪生病的患者的外周血细胞对干扰素的体外反应较差。

获取原文
获取原文并翻译 | 示例
           

摘要

Autoimmune Addison's disease (AAD) is a disorder caused by an immunological attack on the adrenal cortex. The interferon (IFN)-inducible chemokine CXCL10 is elevated in serum of AAD patients, suggesting a peripheral IFN signature. However, CXCL10 can also be induced in adrenocortical cells stimulated with IFNs, cytokines, or microbial components. We therefore investigated whether peripheral blood mononuclear cells (PBMCs) from AAD patients display an enhanced propensity to produce CXCL10 and the related chemokine CXCL9, after stimulation with type I or II IFNs or the IFN inducer poly (I:C). Although serum levels of CXCL10 and CXCL9 were significantly elevated in patients compared with controls, IFN stimulated patient PBMC produced significantly less CXCL10/CXCL9 than control PBMC. Low CXCL10 production was not significantly associated with medication, disease duration, or comorbidities, but the low production of poly (I:C)-induced CXCL10 among patients was associated with an AAD risk allele in the phosphatase nonreceptor type 22 (PTPN22) gene. PBMC levels of total STAT1 and -2, and IFN-induced phosphorylated STAT1 and -2, were not significantly different between patients and controls. We conclude that PBMC from patients with AAD are deficient in their response to IFNs, and that the adrenal cortex itself may be responsible for the increased serum levels of CXCL10.
机译:自身免疫性艾迪生氏病(AAD)是由对肾上腺皮质的免疫攻击引起的疾病。干扰素(IFN)诱导的趋化因子CXCL10在AAD患者的血清中升高,表明存在外周IFN信号。但是,CXCL10也可以在由IFN,细胞因子或微生物成分刺激的肾上腺皮质细胞中被诱导。因此,我们研究了用I型或II型IFN或IFN诱导剂多聚体(I:C)刺激后,来自AAD患者的外周血单核细胞(PBMC)是否显示出增强的产生CXCL10和相关趋化因子CXCL9的倾向。尽管与对照组相比,患者的血清CXCL10和CXCL9水平显着升高,但IFN刺激的患者PBMC产生的CXCL10 / CXCL9明显少于对照组PBMC。 CXCL10的低产生与药物治疗,疾病持续时间或合并症没有显着相关性,但是患者中由聚(I:C)诱导的CXCL10的低产生与22型磷酸酶非受体(PTPN22)基因中的AAD风险等位基因相关。患者和对照组之间的总STAT1和-2以及IFN诱导的磷酸化STAT1和-2的PBMC水平没有显着差异。我们得出的结论是,患有AAD的患者的PBMC对IFN的反应不足,并且肾上腺皮质本身可能与CXCL10血清水平升高有关。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号